ALS2CR7 Inhibitors
Chemical inhibitors of ALS2CR7 function by obstructing its kinase activity, a crucial mechanism for its role in cellular signaling. Palbociclib (PD 0332991), for instance, achieves this by selectively inhibiting related cyclin-dependent kinases such as CDK4 and CDK6, suggesting that it may similarly impair ALS2CR7 by blocking its ability to phosphorylate target proteins. Roscovitine and olomoucine, both purine derivatives, are known to target CDKs by competing with ATP at the kinase binding site. The inhibition offered by these compounds involves the prevention of ATP from binding to the active site of ALS2CR7, thereby directly hindering its kinase activity and its subsequent phosphorylation cascade. Dinaciclib extends this inhibition to a broader spectrum of CDKs and, by extension, possibly to ALS2CR7, by occupying the ATP-binding pocket and precluding enzymatic activity.
Flavopiridol, another CDK inhibitor, along with alsterpaullone, milciclib, and the indirubin derivative indirubin-3'-monoxime, all exhibit similar inhibitory actions, which could translate to direct inhibition of ALS2CR7's kinase function. The interruption of ATP binding by these inhibitors results in impaired phosphorylation ability of ALS2CR7, effectively silencing its functional role in the cell. Additionally, LEE011 (Ribociclib) and AZD5438, both of which target CDK4, CDK6, CDK1, CDK2, and CDK9, are likely to extend their inhibitory potential to ALS2CR7, assuming structural compatibility, by also binding to the ATP site and preventing kinase activation. SNS-032 further reinforces this pattern of inhibition by targeting the ATP-binding site of CDKs, including CDK2, CDK7, and CDK9, suggesting that it can inhibit ALS2CR7 by a similar mechanism of action.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. As ALS2CR7 is related to the CDK family by its gene name CDK15, palbociclib may inhibit CDK15 activity by obstructing its kinase activity, thus preventing phosphorylation of its substrates, which is essential for its function. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine targets various CDKs including CDK2, CDK7, and CDK9. Its mechanism of action involves competitive inhibition at the ATP-binding site of these kinases. If ALS2CR7 shares a similar ATP-binding conformation, roscovitine could inhibit its kinase activity, directly reducing ALS2CR7's functional capacity to phosphorylate target proteins. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a potent inhibitor of several CDKs, notably CDK2, CDK5, CDK1, and CDK9. Its broad-spectrum CDK inhibition suggests that it might also inhibit ALS2CR7 by blocking its ATP-binding site, leading to a decrease in ALS2CR7 kinase activity, and thus a functional inhibition of the protein. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Similar to roscovitine, olomoucine is a purine derivative that inhibits CDKs by competing with ATP for binding to the kinase domain. If ALS2CR7's structure allows for olomoucine binding, this chemical could inhibit ALS2CR7's enzymatic activity, preventing it from phosphorylating its substrates. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A is known to inhibit CDK1, CDK2, and CDK5 by competing with ATP. If ALS2CR7 has a similar ATP-binding site, purvalanol A could hinder ATP binding, thereby inhibiting its kinase activity and subsequent phosphorylation functions. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Milciclib targets multiple CDKs and might inhibit ALS2CR7 by preventing ATP from binding to its active site, thereby reducing its kinase activity and its ability to phosphorylate target proteins, leading to functional inhibition. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits various CDKs by competing with ATP for the kinase active site. If ALS2CR7 shares structural similarities with these CDKs, flavopiridol could inhibit its kinase activity, and thus its function. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a potent inhibitor of CDK1 and CDK5. By binding to the ATP pocket of these kinases, it may also inhibit ALS2CR7 if the kinase structure and ATP-binding properties are similar, leading to a functional inhibition of ALS2CR7 activity. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
This compound is a known inhibitor of CDKs and GSK-3beta. Through competitive inhibition at the ATP-binding site of these kinases, it could inhibit ALS2CR7 by a similar mechanism, assuming ALS2CR7 has a compatible ATP-binding conformation. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
LEE011 is a selective inhibitor of CDK4 and CDK6, and by extension, could potentially inhibit ALS2CR7 by interfering with ATP binding and kinase activity, pending structural compatibility. | ||||||